This is the authors' abstract. We don't add key points for this paper.
A 48-year-old woman with HIV infection developed Cushingoid features while she was taking ritonavir-boosted darunavir. Cushing's syndrome was confirmed due to the drug interaction between ritonavir and budesonide. Diagnosis of iatrogenic Cushing's syndrome in HIV-positive patients who are on ritonavir-boosted protease inhibitors (PIs) presents a clinical challenge due to similar clinical features of lipohypertrophy related to ritonavir-boosted PIs. Although this complication has been widely described with the use of inhaled fluticasone, the interaction with inhaled budesonide at therapeutic dose is not widely recognized.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Yoganathan et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: